United Therapeutics (UTHR) EBITDA Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -164.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -611.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -572.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -194.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -341.00 |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -538.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -341.00 |
| Mar 31, 2026 | -650.00 |
| Dec 31, 2025 | -347.00 |
| Sep 30, 2025 | 278.00 |
| Jun 30, 2025 | 89.00 |
| Mar 31, 2025 | -439.00 |
| Dec 31, 2024 | 629.00 |
| Sep 30, 2024 | -785.00 |
| Jun 30, 2024 | -779.00 |
| Mar 31, 2024 | -353.00 |
| Dec 31, 2023 | 659.00 |
| Sep 30, 2023 | -725.00 |
| Jun 30, 2023 | 932.00 |
| Mar 31, 2023 | -625.00 |
| Dec 31, 2022 | -517.00 |
| Sep 30, 2022 | 948.00 |
| Jun 30, 2022 | -654.00 |
| Mar 31, 2022 | 7,944.00 |
| Dec 31, 2021 | 2,393.00 |
| Sep 30, 2021 | -674.00 |